Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Lee

Showing results (291-300 of 314) with videos related to

Pageof 32
Sort By:
JCO Precision Oncology|August 12, 2021
<i>TERT</i> Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional RecurrenceYao Yu, Dan Fan, Xinmao Song, et al.
Oncotarget|November 19, 2016
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancerEvelyn Kidess-Sigal, Haiyan E Liu, Melanie M Triboulet, et al.
Cancer Research and Treatment|April 5, 2022
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL)Kyoung Ha Kim, Jae Hoon Lee, Mark Lee, et al.
Circulation|June 16, 2022
Frequency, Penetrance, and Variable Expressivity of Dilated Cardiomyopathy-Associated Putative Pathogenic Gene Variants in UK Biobank ParticipantsRavi A Shah, Babken Asatryan, Ghaith Sharaf Dabbagh, et al.
Head & Neck|December 16, 2022
Clinical outcomes of combined cervical and transthoracic surgical approaches in patients with advanced thyroid cancerJared A Shenson, Mark E Zafereo, Mark Lee, et al.
Pediatric Dermatology|February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled TrialLawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
JACC. Cardiovascular Imaging|April 13, 2024
Cardiovascular Magnetic Resonance Reference Ranges From the Healthy Hearts ConsortiumZahra Raisi-Estabragh, Liliana Szabo, Celeste McCracken, et al.
The British Journal of Dermatology|June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb studyLeon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
The Journal of Clinical Investigation|August 10, 2023
Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinomaCristina Valero, Mahdi Golkaram, Joris L Vos, et al.
European Urology|May 20, 2014
A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersamplingEric A Klein, Matthew R Cooperberg, Cristina Magi-Galluzzi, et al.
Pageof 32

Showing results (291-300 of 314) with videos related to

Sort By:
Pageof 32
JCO Precision Oncology|August 12, 2021
<i>TERT</i> Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional RecurrenceYao Yu, Dan Fan, Xinmao Song, et al.
Oncotarget|November 19, 2016
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancerEvelyn Kidess-Sigal, Haiyan E Liu, Melanie M Triboulet, et al.
Cancer Research and Treatment|April 5, 2022
Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study bythe Consortium for Improving Survival of Lymphoma (CISL)Kyoung Ha Kim, Jae Hoon Lee, Mark Lee, et al.
Circulation|June 16, 2022
Frequency, Penetrance, and Variable Expressivity of Dilated Cardiomyopathy-Associated Putative Pathogenic Gene Variants in UK Biobank ParticipantsRavi A Shah, Babken Asatryan, Ghaith Sharaf Dabbagh, et al.
Head & Neck|December 16, 2022
Clinical outcomes of combined cervical and transthoracic surgical approaches in patients with advanced thyroid cancerJared A Shenson, Mark E Zafereo, Mark Lee, et al.
Pediatric Dermatology|February 21, 2025
Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Randomized Controlled TrialLawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, et al.
JACC. Cardiovascular Imaging|April 13, 2024
Cardiovascular Magnetic Resonance Reference Ranges From the Healthy Hearts ConsortiumZahra Raisi-Estabragh, Liliana Szabo, Celeste McCracken, et al.
The British Journal of Dermatology|June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb studyLeon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.
The Journal of Clinical Investigation|August 10, 2023
Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinomaCristina Valero, Mahdi Golkaram, Joris L Vos, et al.
European Urology|May 20, 2014
A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersamplingEric A Klein, Matthew R Cooperberg, Cristina Magi-Galluzzi, et al.
Pageof 32